youtube_live
Q3 2026 pajamos • išleista • Pajamos iš vienos akcijos viršijo lūkesčius +17,88% • Pajamos viršijo lūkesčius +7,88%
Žr. rezultatuschevron_right
LILY34:BVMF
Eli Lilly and Company
247,23 BRL
arrow_upward
+7,28%(+16,78) 1 D.
10-29, 17:06:00 GMT−3 · BRL
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „LILY34“ įžvalgos...
Atidaryti
237,93 BRL
Aukšta
251,28 BRL
Žema
237,93 BRL
Rinkos kapitalizacija
1,29 trln.
Vid. kiekis
46,08 tūkst.
Apimtis
64,69 tūkst.
52 sav. aukšta
251,28 BRL
52 sav. žema
141,70 BRL
Neapmokėtos akcijos
941,36 mln.
Darbuotojų skaičius
50 tūkst.
Atidaryti
237,93 BRL
Aukšta
251,28 BRL
Žema
237,93 BRL
Rinkos kapitalizacija
1,29 trln.
Vid. kiekis
46,08 tūkst.
Apimtis
64,69 tūkst.
52 sav. aukšta
251,28 BRL
52 sav. žema
141,70 BRL
Neapmokėtos akcijos
941,36 mln.
Darbuotojų skaičius
50 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Yahoo! Finance Canada
·
prieš 4 minutes
Eli Lilly and Company (LLY.SW) Seasonal Returns Chart - Yahoo Finance
재경일보
·
prieš 1 valandą
Eli Lilly Shares Jump 6.6% as Mounjaro and Zepbound Fuel Third-Quarter Earnings Beat : Finance : JKN
Barron's
·
prieš 2 valandas
Eli Lilly Stock Jumps on Monster Earnings as Finance Chief Eyes Next Growth Engine
Morningstar
·
prieš 2 valandas
Eli Lilly Earnings: Medicare Zepbound Demand Outpaced Our Expectations, but Shares Overvalued
Profilis
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
Apie „Eli Lilly and Company“
Generalinis direktoriusDavid A. Ricks
Darbuotojai50 tūkst.
Įkurta1876
Pagrindinė būstinėIndianapolis, Indiana, Jungtinės Valstijos
Sektorius-
Svetainėlilly.com